Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952597 | 1.00 | DPP4 (0.36) | DPP4DPP8DPP7CYP2D6NOTCH1 | |
| SCHEMBL18952596 | 1.00 | DPP4 (0.36) | DPP4DPP8DPP7CYP2D6NOTCH1 | |
| SCHEMBL21726853 | 0.81 | CA2 (0.42) | DPP4DPP8DPP7PSEN1PSEN2 | |
| SCHEMBL21726855 | 0.81 | CA2 (0.42) | DPP4DPP8DPP7PSEN1PSEN2 | |
| SCHEMBL18952546 | 0.81 | CA2 (0.42) | DPP4DPP8DPP7PSEN1PSEN2 | |
| SCHEMBL18970974 | 0.81 | CA2 (0.42) | DPP4DPP8DPP7PSEN1PSEN2 | |
| SCHEMBL20609131 | 0.81 | PSEN1 (0.39) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18971472 | 0.81 | PSEN1 (0.39) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20609130 | 0.81 | PSEN1 (0.39) | DPP4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20609175 | 0.81 | PSEN1 (0.42) | NOTCH1PSEN1PSEN2KCNH2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | DPP4 4282/4885DPP8 3710/4885DPP7 3496/4885 |
| US-10562903-B2 | Bridged piperidine derivatives | PTGDR, HPGDS, PSEN1 | DPP4 4282/4885DPP8 3710/4885DPP7 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.